查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
再生医学市场：按成分、按产品、按材料、按应用、按最终用户、按地区、机会、预测，2017-2031
市场调查报告书
商品编码
1422066

再生医学市场：按成分、按产品、按材料、按应用、按最终用户、按地区、机会、预测，2017-2031

Regenerative Medicine Market Assessment, By Component, By Product, By Material, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 235 Pages | 商品交期: 3-5个工作天内

价格

全球再生医学市场规模预计将从 2023 年的 249.1 亿美元增长到 2031 年的 999.5 亿美元，预测期内复合年增长率为 18.97%。

全球再生医学市场受到人口老化加剧、慢性病盛行率上升、技术进步、投资增加、病患需求增加以及有利的报销政策等因素的推动。

慢性病盛行率上升

慢性病的增加是全球再生医学市场的关键驱动力。 世界卫生组织（WHO）强调，心血管疾病、癌症、糖尿病、呼吸道疾病等慢性病正以惊人的速度成长。 如果目前的趋势持续下去，世界卫生组织预测，到 2050 年，每年 9,000 万人死亡中的 86% 将死于慢性病。 由于相关的医疗负担和传统治疗的局限性，慢性病的增加令人担忧。 再生医学透过专注于修復和替换受损组织并有效地针对慢性疾病的根本原因，为解决这些健康挑战提供了一条有前途的途径。 因此，日益增加的慢性病负担已成为再生医学市场成长的强大驱动力，再生医学市场寻求提供创新和更有效的解决方案。

扩大研发投入

基因治疗解决方案的研发投资在推动全球再生医学市场方面发挥着至关重要的作用。 基因疗法有可能纠正遗传缺陷、操纵细胞功能并从根源解决各种疾病。 这种有针对性的方法由于其再生和修復受损组织的能力而获得了大量的财政支持。 投资将促进创新，加速新的再生医学治疗方法的开发，最终为全球再生医学市场的成长和发展做出贡献，为以前无法治疗的疾病带来希望，并改善整体医疗保健状况。

政府措施

世界各国政府越来越认识到再生医学领域的巨大潜力，并积极采取措施促进其使用和扩展。 各国政府将透过资助研发、建立安全有效部署治疗的监管结构以及加强再生医学解决方案生产和分配所需的基础设施来采取这些措施。

基因治疗的需求不断增加

在全球再生医学市场，基因治疗的需求正在快速成长。 基因疗法因其能够解决多种遗传疾病、慢性病和未满足的医疗需求而获得发展势头。 随着基因疗法研究和技术的不断进步，其有效性和安全性正在得到保证。 因此，随着需求的增加以及患者和医疗保健专业人员寻求基因疗法的替代疗法，基因疗法被定位为再生医学领域的潜在途径。

本报告调查了全球再生医学市场，提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素分析、案例研究、竞争格局、主要公司的简介等等。

目录

第 1 章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第 4 章全球再生医学市场展望

  • 市场规模/预测
  • 按组件
    • 治疗学
    • 工具
    • 银行
    • 服务
  • 按产品
    • 基因治疗
    • 细胞疗法
    • 人体组织工程
    • 器官治疗
    • 小分子和生物製剂
  • 依材质
    • 合成材料
    • 生物材料
    • 基因改造材料
    • 其他
  • 依用途
    • 伤口护理
    • 肌肉骨骼系统
    • 眼科
    • 肿瘤
    • 心血管
    • 皮肤科
    • 神经病学
    • 其他
  • 按最终用户
    • 医院
    • 诊所
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 南美洲
    • 亚太地区
    • 中东/非洲
  • 各公司的市占率

第 5 章全球再生医学市场展望：按地区

  • 北美
  • 欧洲
  • 南美洲
  • 亚太地区
  • 中东/非洲

第 6 章市场映射

  • 按组件
  • 按产品
  • 依材质
  • 依用途
  • 按最终用户
  • 按地区

第 7 章宏观环境与产业结构

  • 需求与供给分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 成长促进因素
  • 成长抑制因素（问题/障碍）

第 9 章监理架构/创新

  • 临床试验
  • 专利情况
  • 监理机关的核准
  • 创新/最新技术

第 10 章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析
  • 併购/合资企业（如果适用）
  • SWOT 分析（5 家参与公司）
  • 专利分析（如果适用）

第 11 章价格分析

第 12 章案例研究

第 13 章主要公司展望

  • Novartis AG
  • Athersys, Inc.
  • Vericel Corporation
  • Biogen, Inc.
  • Becton, Dickinson, and Company
  • Takeda Pharmaceutical Company
  • Sarepta Therapeutics Inc.
  • Amgen, Inc.
  • Smith & Nephew plc
  • JCR Pharmaceuticals Co., Ltd.
  • Gilead Sciences Inc.
  • Abbvie Inc.

第 14 章策略建议

第 15 章关于我们公司/免责声明

Product Code: MX10931

Global regenerative medicine market size was valued at USD 24.91 billion in 2023, expected to reach USD 99.95 billion in 2031, with a CAGR of 18.97% for the forecast period between 2024 and 2031. The global regenerative medicine market is driven by factors such as a growing aging population, increasing prevalence of chronic diseases, technological advancements, growing investments, increasing patient demand, and favorable reimbursement policies.

The global regenerative medicine market is undergoing rapid expansion. With an increasing elderly demographic, the prevalence of age-related health issues, chronic diseases, and cases related to tissue degeneration have increased significantly. Conditions such as diabetes, cardiovascular diseases, and neurodegenerative disorders are increasing globally, fuelling the demand for global regenerative medicine market interventions that can repair or replace damaged tissues. Regulatory agencies have recognized regenerative medicine's potential and created pathways and guidelines for product approval and commercialization. Collaborative efforts across various sectors, including pharmaceutical companies, biotechnology firms, academic institutions, and research organizations, have facilitated the development of innovative regenerative medicine products. These partnerships accelerate research and development, resulting in more accessible patient treatments.

Technological advancements in the global regenerative medicine market, such as stem cell research and gene therapy, have expanded the possibilities in regenerative medicine, making treatments more effective and versatile. With patients becoming more aware of regenerative medicine's potential, there is an increasing demand for these innovative therapies. Favorable reimbursement policies and government support in some regions have further encouraged accessibility. Ethical concerns, particularly regarding stem cell research, have hindered the development of alternative methods like induced pluripotent stem cells (iPSCs). The trend toward personalized medicine has reinforced the importance of customizing regenerative medicine treatments based on individual genetic makeup, further enhancing the growth and potential of global regenerative medicine market. These factors collectively propel the regenerative medicine market into a promising and dynamic sector within the healthcare industry, though challenges such as regulatory hurdles and development costs still need to be addressed for sustainable growth.

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases is a significant catalyst for the global regenerative medicine market. Chronic diseases, as highlighted by the World Health Organization (WHO), including cardiovascular diseases, cancer, diabetes, and respiratory illnesses, have been increasing at an alarming rate. WHO's projections indicate that if the trend persists, by the year 2050, chronic diseases will contribute to a staggering 86% of the estimated 90 million annual deaths. The increase in chronic diseases is a cause for concern due to the associated healthcare burden and the limitations of conventional treatments. Regenerative medicine offers a promising avenue to address these health challenges by focusing on repairing or replacing damaged tissues, effectively targeting the root causes of these chronic conditions. As a result, the escalating burden of chronic diseases is a strong driver for the growth of the regenerative medicine market, as it seeks to provide innovative and more effective solutions.

Growing Investments in Research and Development

Investments in research and development in gene therapy solutions have played a pivotal role in propelling the global regenerative medicine market. Gene therapy can potentially correct genetic defects, manipulate cellular functions, and address various diseases at their source. The targeted approach has generated substantial financial support with its ability to regenerate or repair damaged tissues. Investments are driving innovation and accelerating the development of novel regenerative medicine treatments, ultimately contributing to the growth and expansion of the global regenerative medicine market, offering hope for previously untreatable conditions, and enhancing the overall healthcare landscape.

In September 2023, TherageniX, a startup from the University of Nottingham, which specializes in a dry powder gene therapy formulation to enhance bone graft augmentation, received a grant of approx. GBP 995 thousand from Innovate UK, the innovation agency of the United Kingdom, in collaboration with the University of Nottingham. The financial support is earmarked for advancing the company's work on a powder-form non-viral gene delivery system, aimed at enhancing tissue regeneration post-surgery.

Government Initiatives

Governments around the globe are increasingly acknowledging the substantial potential in the regenerative medicine domain and are actively implementing measures to promote its usage and expansion. The government is taking these measures through financing research and development, establishing regulatory structures for the safe and efficient deployment of treatments, and bolstering the infrastructure required for the production and distribution of regenerative medical solutions. Investment in regenerative medicine catalyzes innovation and positions nations to become leaders in the rapidly growing sector. By nurturing an environment conducive to scientific exploration and commercial advancement, governments aspire to enhance healthcare outcomes, address unmet medical needs, and contribute to advancing the global regenerative medicine market.

In June 2023, the Indian central government inaugurated India's inaugural center dedicated to regenerative therapies for repairing damaged corneas in Delhi. The facility enables patients to receive bioengineered cornea treatment, harnessing tissue-specific exosomes and biomaterials mimicking natural tissues to stimulate the regeneration of robust and functional corneas. The treatment involves applying liquid drops directly onto the cornea, which solidifies in under 10 minutes, seamlessly integrating with the patient's existing corneal tissue.

Increasing Demand for Gene Therapy

There has been a notable surge in demand for gene therapy in the global regenerative medicine market. Gene therapy is gaining momentum due to its capacity to tackle various genetic disorders, chronic ailments, and unaddressed medical requirements. As gene therapy research and technologies continue to progress, there is assurance over its efficacy and safety. As a result, demand is increasing, and gene therapy is being positioned as a potential path in the field of regenerative medicine as patients and healthcare professionals are increasingly looking for gene therapy alternatives.

In June 2023, Sarepta Therapeutics, Inc., a frontrunner in precise genetic medicine for rare diseases, unveiled that the U.S. Food and Drug Administration (FDA) approved ELEVIDYS (delandistrogene moxeparvovec-rokl). A gene therapy that utilizes an adeno-associated virus for the treatment of ambulatory pediatric patients between the ages of 4 and 5 years who have been diagnosed with Duchenne muscular dystrophy (DMD) and possess a confirmed mutation in the DMD gene.

Regenerative Medicines for Ophthalmology

The growing demand for regenerative medicines in ophthalmology is proving to be a substantial asset to the global regenerative medicine market. The surge is primarily attributed to the prevalence of ocular conditions like age-related macular degeneration, corneal diseases, and retinal disorders, which can result in vision impairments or blindness. Regenerative medicines present effective solutions by applying stem cells, gene therapies, and tissue engineering to rectify damaged eye tissues and rejuvenate vision. With the aging population continually increasing, the request for these cutting-edge treatments in the ophthalmology is growing rapidly, actively contributing to the overall expansion of the global regenerative medicine market and instilling optimism for enhanced eye health and visual outcomes.

In August 2023, ViGeneron GmbH disclosed that the European Medicines Agency (EMA) had granted its clinical trial application (CTA) approval for the novel gene therapy, VG901. ViGeneron reports that VG901 utilizes an adeno-associated virus (AAV) vector to treat CNGA1-associated retinitis pigmentosa (RP).

Future Market Scenario

The global regenerative medicine market is expected to grow rapidly due to the convergence of multiple influential factors. Primarily, the increasing global aging demographic has led to a higher incidence of chronic illnesses, degenerative ailments, and tissue damage, thereby creating a demand for advanced regenerative therapies. Additionally, breakthroughs in fields such as stem cell research, gene therapy, and tissue engineering have broadened the horizons of regenerative medicine, enhancing the effectiveness and versatility of treatments.

Furthermore, government support and the recognition by regulatory agencies of regenerative medicine's potential have resulted in the establishment of guidelines and pathways for product development and approval. It has instilled greater confidence in investors and expedited research efforts. Collaborative ventures involving pharmaceutical companies, research institutions, and biotechnology firms are expected to spur the innovation ahead.

Key Players Landscape and Outlook

Companies are progressively establishing strategic partnerships and distribution agreements, which are pivotal in propelling the global regenerative medicine market's expansion. These alliances empower firms to harness each other's strengths, gain access to new markets, and pool resources for research and development endeavors. Distribution agreements enable companies to broaden their market presence and enhance the accessibility of regenerative medicine treatments to a wider patient demographic. These collaborative initiatives promote innovation, expedite product development, and, in the end, contribute to the enduring and robust growth of the regenerative medicine market.

In August 2023, Marrow Access Technologies unveiled a distribution agreement with Spartan Medical. The agreement is set to grant patients in the Department of Veterans Affairs (VA) and Department of Defense (DoD) access to the SmartShot Marrow Access Device. The innovative device offers a unique solution, harnessing the body's inherent stem cells and regenerative potential to address orthopedic soft tissue injuries affecting areas like the knee, hip, shoulder, foot, and ankle.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Regenerative Medicine Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. Value
    • 4.1.2. Volume
  • 4.2. By Component
    • 4.2.1. Therapeutics
    • 4.2.2. Tools
    • 4.2.3. Banks
    • 4.2.4. Services
  • 4.3. By Product
    • 4.3.1. Gene Therapy
    • 4.3.2. Cell Therapy
      • 4.3.2.1. Stem Cell Therapy
      • 4.3.2.1.1. Autologous Therapy
      • 4.3.2.1.2. Allogenic Therapy
    • 4.3.3. Tissue Engineering
    • 4.3.4. Organ Therapy
    • 4.3.5. Small Molecules and Biologics
  • 4.4. By Material
    • 4.4.1. Synthetic Material
    • 4.4.2. Biologically Derived Material
    • 4.4.3. Genetically Engineered Material
    • 4.4.4. Others
  • 4.5. By Application
    • 4.5.1. Wound Care
    • 4.5.2. Musculoskeletal
    • 4.5.3. Ophthalmology
    • 4.5.4. Oncology
    • 4.5.5. Cardiovascular
    • 4.5.6. Dermatology
    • 4.5.7. Neurology
    • 4.5.8. Others
  • 4.6. By End-user
    • 4.6.1. Hospitals
    • 4.6.2. Clinics
    • 4.6.3. Others
  • 4.7. By Region
    • 4.7.1. North America
    • 4.7.2. Europe
    • 4.7.3. South America
    • 4.7.4. Asia-Pacific
    • 4.7.5. Middle East and Africa
  • 4.8. By Company Market Share (%), 2023

5. Global Regenerative Medicine Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. Value
      • 5.1.1.2. Volume
    • 5.1.2. By Component
      • 5.1.2.1. Therapeutics
      • 5.1.2.2. Tools
      • 5.1.2.3. Banks
      • 5.1.2.4. Services
    • 5.1.3. By Product
      • 5.1.3.1. Gene Therapy
      • 5.1.3.2. Cell Therapy
      • 5.1.3.2.1. Stem Cell Therapy
      • 5.1.3.2.1.1. Autologous Therapy
      • 5.1.3.2.1.2. Allogenic Therapy
      • 5.1.3.3. Tissue Engineering
      • 5.1.3.4. Organ Therapy
      • 5.1.3.5. Small Molecules and Biologics
    • 5.1.4. By Material
      • 5.1.4.1. Synthetic Material
      • 5.1.4.2. Biologically Derived Material
      • 5.1.4.3. Genetically Engineered Material
      • 5.1.4.4. Others
    • 5.1.5. By Application
      • 5.1.5.1. By Application
      • 5.1.5.2. Wound Care
      • 5.1.5.3. Musculoskeletal
      • 5.1.5.4. Ophthalmology
      • 5.1.5.5. Oncology
      • 5.1.5.6. Cardiovascular
      • 5.1.5.7. Dermatology
      • 5.1.5.8. Neurology
      • 5.1.5.9. Others
    • 5.1.6. By End-user
      • 5.1.6.1. Hospitals
      • 5.1.6.2. Clinics
      • 5.1.6.3. Others
    • 5.1.7. United States*
      • 5.1.7.1. Market Size & Forecast
      • 5.1.7.1.1. Value
      • 5.1.7.1.2. Volume
      • 5.1.7.2. By Component
      • 5.1.7.2.1. Therapeutics
      • 5.1.7.2.2. Tools
      • 5.1.7.2.3. Banks
      • 5.1.7.2.4. Services
      • 5.1.7.3. By Product
      • 5.1.7.3.1. Gene Therapy
      • 5.1.7.3.2. Cell Therapy
      • 5.1.7.3.2.1. Stem Cell Therapy
      • 5.1.7.3.2.1.1. Autologous Therapy
      • 5.1.7.3.2.1.2. Allogenic Therapy
      • 5.1.7.3.3. Tissue Engineering
      • 5.1.7.3.4. Organ Therapy
      • 5.1.7.3.5. Small Molecules and Biologics
      • 5.1.7.4. By Material
      • 5.1.7.4.1. Synthetic Material
      • 5.1.7.4.2. Biologically Derived Material
      • 5.1.7.4.3. Genetically Engineered Material
      • 5.1.7.4.4. Others
      • 5.1.7.5. By Application
      • 5.1.7.5.1. Wound Care
      • 5.1.7.5.2. Musculoskeletal
      • 5.1.7.5.3. Ophthalmology
      • 5.1.7.5.4. Oncology
      • 5.1.7.5.5. Cardiovascular
      • 5.1.7.5.6. Dermatology
      • 5.1.7.5.7. Neurology
      • 5.1.7.5.8. Others
      • 5.1.7.6. By End-user
      • 5.1.7.6.1. Hospitals
      • 5.1.7.6.2. Clinics
      • 5.1.7.6.3. Others
    • 5.1.8. Canada
    • 5.1.9. Mexico

All segments will be provided for all regions and countries covered:

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. South America
    • 5.3.1. Brazil
    • 5.3.2. Argentina
  • 5.4. Asia-Pacific
    • 5.4.1. India
    • 5.4.2. China
    • 5.4.3. Japan
    • 5.4.4. Australia
    • 5.4.5. Vietnam
    • 5.4.6. South Korea
    • 5.4.7. Indonesia
    • 5.4.8. Philippines
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Component
  • 6.2. By Product
  • 6.3. By Material
  • 6.4. By Application
  • 6.5. By End-user
  • 6.6. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Novartis AG
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Athersys, Inc.
  • 13.3. Vericel Corporation
  • 13.4. Biogen, Inc.
  • 13.5. Becton, Dickinson, and Company
  • 13.6. Takeda Pharmaceutical Company
  • 13.7. Sarepta Therapeutics Inc.
  • 13.8. Amgen, Inc.
  • 13.9. Smith & Nephew plc
  • 13.10. JCR Pharmaceuticals Co., Ltd.
  • 13.11. Gilead Sciences Inc.
  • 13.12. Abbvie Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 4. Global Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 5. Global Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 6. Global Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 7. Global Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 8. Global Regenerative Medicine Market Share (%), By Region, 2017-2031F
  • Figure 9. North America Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 10. North America Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 11. North America Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 12. North America Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 13. North America Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 14. North America Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 15. North America Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 16. North America Regenerative Medicine Market Share (%), By Country, 2017-2031F
  • Figure 17. United States Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 18. United States Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 19. United States Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 20. United States Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 21. United States Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 22. United States Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 23. United States Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 24. Canada Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 25. Canada Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 26. Canada Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 27. Canada Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 28. Canada Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 29. Canada Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 30. Canada Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 31. Mexico Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 32. Mexico Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 33. Mexico Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 34. Mexico Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 35. Mexico Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 36. Mexico Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 37. Mexico Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 38. Europe Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 39. Europe Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 40. Europe Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 41. Europe Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 42. Europe Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 43. Europe Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 44. Europe Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 45. Europe Regenerative Medicine Market Share (%), By Country, 2017-2031F
  • Figure 46. Germany Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. Germany Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. Germany Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 49. Germany Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 50. Germany Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 51. Germany Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 52. Germany Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 53. France Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 54. France Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 55. France Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 56. France Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 57. France Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 58. France Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 59. France Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 60. Italy Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Italy Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 62. Italy Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 63. Italy Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 64. Italy Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 65. Italy Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 66. Italy Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 67. United Kingdom Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 68. United Kingdom Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 69. United Kingdom Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 70. United Kingdom Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 71. United Kingdom Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 72. United Kingdom Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 73. United Kingdom Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 74. Russia Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 75. Russia Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 76. Russia Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 77. Russia Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 78. Russia Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 79. Russia Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 80. Russia Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 81. Netherlands Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 82. Netherlands Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 83. Netherlands Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 84. Netherlands Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 85. Netherlands Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 86. Netherlands Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 87. Netherlands Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 88. Spain Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Spain Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Spain Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 91. Spain Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 92. Spain Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 93. Spain Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 94. Spain Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 95. Turkey Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 96. Turkey Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 97. Turkey Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 98. Turkey Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 99. Turkey Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 100. Turkey Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 101. Turkey Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 102. Poland Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. Poland Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 104. Poland Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 105. Poland Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 106. Poland Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 107. Poland Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 108. Poland Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 109. South America Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 110. South America Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 111. South America Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 112. South America Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 113. South America Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 114. South America Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 115. South America Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 116. South America Regenerative Medicine Market Share (%), By Country, 2017-2031F
  • Figure 117. Brazil Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 118. Brazil Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 119. Brazil Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 120. Brazil Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 121. Brazil Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 122. Brazil Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 123. Brazil Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 124. Argentina Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 125. Argentina Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 126. Argentina Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 127. Argentina Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 128. Argentina Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 129. Argentina Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 130. Argentina Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 131. Asia-Pacific Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 132. Asia-Pacific Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 133. Asia-Pacific Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 134. Asia-Pacific Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 135. Asia-Pacific Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 136. Asia-Pacific Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 137. Asia- Pacific Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 138. Asia-Pacific Regenerative Medicine Market Share (%), By Country, 2017-2031F
  • Figure 139. India Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 140. India Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 141. India Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 142. India Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 143. India Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 144. India Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 145. India Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 146. China Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 147. China Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 148. China Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 149. China Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 150. China Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 151. China Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 152. China Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 153. Japan Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 154. Japan Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 155. Japan Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 156. Japan Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 157. Japan Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 158. Japan Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 159. Japan Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 160. Australia Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 161. Australia Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 162. Australia Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 163. Australia Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 164. Australia Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 165. Australia Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 166. Australia Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 167. Vietnam Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. Vietnam Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 169. Vietnam Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 170. Vietnam Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 171. Vietnam Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 172. Vietnam Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 173. Vietnam Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 174. South Korea Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 175. South Korea Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 176. South Korea Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 177. South Korea Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 178. South Korea Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 179. South Korea Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 180. South Korea Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 181. Indonesia Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. Indonesia Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. Indonesia Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 184. Indonesia Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 185. Indonesia Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 186. Indonesia Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 187. Indonesia Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 188. Philippines Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 189. Philippines Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 190. Philippines Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 191. Philippines Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 192. Philippines Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 193. Philippines Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 194. Philippines Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 195. Middle East & Africa Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 196. Middle East & Africa Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 197. Middle East & Africa Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 198. Middle East & Africa Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 199. Middle East & Africa Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 200. Middle East & Africa Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 201. Middle East & Africa Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 202. Middle East & Africa Regenerative Medicine Market Share (%), By Country, 2017-2031F
  • Figure 203. Saudi Arabia Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 204. Saudi Arabia Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 205. Saudi Arabia Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 206. Saudi Arabia Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 207. Saudi Arabia Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 208. Saudi Arabia Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 209. Saudi Arabia Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 210. UAE Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 211. UAE Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 212. UAE Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 213. UAE Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 214. UAE Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 215. UAE Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 216. UAE Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 217. South Africa Regenerative Medicine Market, By Value, In USD Billion, 2017-2031F
  • Figure 218. South Africa Regenerative Medicine Market, By Volume, In Million Units, 2017-2031F
  • Figure 219. South Africa Regenerative Medicine Market Share (%), By Component, 2017-2031F
  • Figure 220. South Africa Regenerative Medicine Market Share (%), By Product, 2017-2031F
  • Figure 221. South Africa Regenerative Medicine Market Share (%), By Material, 2017-2031F
  • Figure 222. South Africa Regenerative Medicine Market Share (%), By Application, 2017-2031F
  • Figure 223. South Africa Regenerative Medicine Market Share (%), By End-user, 2017-2031F
  • Figure 224. By Component Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226. By Material Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023